# Envista Holdings Corporation account plan

> Envista is a family of more than 30 dental brands, including Nobel Biocare, Ormco, DEXIS and Kerr, with FY2025 sales of $2,719.5 million.

## At a glance

Envista Holdings Corporation owns more than 30 dental brands, including Nobel Biocare, Ormco, DEXIS and Kerr, covering implants, orthodontics, digital imaging, restoratives, endodontics and infection prevention. It serves dentists, specialists, dental laboratories and Dental Service Organizations (DSOs) in over 130 countries; about 42% of products went through third-party distributors in 2025. FY2025 sales were $2,719.5 million (+8.3%), operating profit $216.1 million and net income $47.0 million, with approximately 12,000 employees at December 31, 2025. It was formed in 2018 within Danaher and became independent through its 2019 IPO.

## Business units

- **Specialty Products & Technologies** (64% of FY2025 sales ($1,752.8 million)): Dental implant systems (Nobel Biocare, Alpha-Bio Tec, Implant Direct), regenerative products, prosthetics and treatment software, plus orthodontics (Ormco, Damon, Spark clear aligners) and loupes, 84% sold direct to end users. FY2025 operating margin was 10.9%. Q3 2026 sales were $443.7 million (core +2.0%), with emerging markets down on China.
- **Equipment & Consumables** (36% of FY2025 sales ($966.7 million)): Imaging systems and software (DEXIS, i-CAT, DTX Studio), endodontics, restoratives and infection prevention (Kerr, Metrex, CaviWipes), about 89% sold through channel partners. FY2025 operating margin was 16.3%. Q3 2026 sales were $247.8 million (core +4.1%), with a 25.1% operating margin lifted by tariff refunds.

## Strategic priorities

- **Growth, Operations and People**: The three company priorities: innovation and commercialization, the Envista Business System for manufacturing performance, and leadership and talent development.
- **Commercialize the new product pipeline**: Recent launches include the S series implant, NOMAD Pro 3 handheld X-ray, DTX Studio Endo Module with AI-assisted canal segmentation and ZenSeal Pro; management says most launches are still below their long-term potential.
- **Gross margin expansion across the portfolio in 2027**: Gross margin has expanded for 3 consecutive quarters; levers are Spark unit cost reduction, diagnostics software and services, and cost of goods sold.
- **Spark clear aligners and diagnostics share gains**: Spark shipped its one millionth case in 2025 and grew high single digits in Q3 2026; Envista says it is the #1 player in North American diagnostics.
- **Emerging markets and DSOs**: Emerging markets were about $586 million of FY2025 sales, and DSOs are named as a fast-growing customer segment to serve at scale.

## Latest results

In Q3 2026 (quarter ended October 2, 2026) sales were $691.5 million, up 3.2% with core growth of 2.7%; nine-month sales were $2,127.5 million, up 8.1%. Developed markets grew core 3.5% while emerging markets grew only 0.4% as China declined ahead of volume-based procurement (VBP). Adjusted EBITDA was about $106 million (15.3% margin) and adjusted EPS $0.40. GAAP net income of $508.3 million included a $428.1 million non-cash foreign currency translation gain from dissolving legal entities. 2026 guidance was raised to core growth of 3.75% to 4.25% and adjusted EPS of $1.54 to $1.58.

## Investments and deals

- **Versah acquisition**: Versah (Densah burs for osseodensification) was acquired on February 2, 2026 for about $54.4 million; it is one of three bolt-on implant acquisitions over the last year.
- **Share buybacks**: A new $300 million program through December 31, 2029 was authorized on May 5, 2026; $111.2 million was repurchased in the first nine months of 2026.
- **New Irvine headquarters**: A lease for building space in Irvine, California was signed on September 2, 2026, with about $34.2 million of fixed payments, commencing early 2028.
- **Restructuring**: Restructuring charges were $29.3 million in 2025 and $22.1 million in the first nine months of 2026.
- **R&D and commercial investment**: R&D was $114.0 million in 2025 (4.2% of sales); nine-month 2026 R&D was $89.7 million (+9.5%).

## Challenges and risks

- **China volume-based procurement**: China is 7%-8% of sales; management expects VBP to cut prices about 50% for orthodontics and 10% to 15% for implants, most likely from the first half of 2027.
- **Tariffs and trade policy**: U.S. tariffs raised costs in 2025; after the IEEPA tariffs were struck down in February 2026, Envista had received $28.2 million of refunds by October 2, 2026.
- **Soft elective demand**: Elective categories such as orthodontics and implants run below historical trends, with U.S. macro uncertainty weighing on patient and clinician confidence.
- **Distributor concentration**: Henry Schein alone was about 12% of 2025 sales, and distributor inventory swings affect results.
- **Regulation and cyber**: The annual report names FDA and EU MDR regulation, cybersecurity and AI use, and indebtedness of approximately $1.5 billion as of February 6, 2026 among the main risks.

## What leadership says

> "in terms of growth, we think of VBP as a good guy. In terms of margin, we think of it as a bad guy." — Paul Keel, President and Chief Executive Officer, Envista Q3 2026 earnings call, November 4, 2026

> "you should expect continued gross and EBITDA margin expansion from total Envista in 2027." — Paul Keel, President and Chief Executive Officer, Envista Q3 2026 earnings call, November 4, 2026

> "The dental market continued to show its characteristic resilience as patient demand for dental care remained stable despite macro pressures." — Paul Keel, President and Chief Executive Officer, Envista Q2 2026 earnings call, August 5, 2026


## Where a supplier can help

- **Manufacturing cost reduction**: The goal of broader gross margin expansion in 2027, with the bigger opportunity on cost of goods sold and Spark unit cost reduction, suits automation, materials and lean operations suppliers.
- **Supply chain and trade compliance**: Tariff exposure and the plan to offset tariffs through supply chain and pricing actions point to sourcing, trade compliance and logistics services.
- **Commercial enablement for launches**: The priority to commercialize a rich pipeline across more than 3,000 commercial employees fits sales enablement, clinical education and marketing tools, including for DSO accounts.
- **Software, AI and cybersecurity**: DTX Studio software with AI tools and the named cyber and AI-use risks create room for cloud, AI and security vendors.

_Tamtam's reading of the priorities and challenges above, not the company's own words._

## Key documents

### [Envista Holdings Corporation Annual Report on Form 10-K for fiscal year 2025](https://www.sec.gov/Archives/edgar/data/1757073/000175707326000011/nvst-20251231.htm)

Annual report · 2026-02-12

- Envista is a global family of more than 30 dental brands (Nobel Biocare, Ormco, DEXIS, Kerr among them), spun out of Danaher (formed 2018, IPO 2019); it serves dental professionals in over 130 countries with approximately 12,000 employees (about 3,000 in the U.S.).
- FY2025 sales were $2,719.5 million, up 8.3% (core sales +6.5%, currency +1.6%); about 85% of sales came from consumable products, services and spare parts.
- Two segments: Specialty Products & Technologies (implants, orthodontics; 64% of sales, $1,752.8 million, operating margin 10.9%) and Equipment & Consumables (imaging, consumables; 36%, $966.7 million, operating margin 16.3%).
- Back to profit: operating profit $216.1 million (7.9% of sales) and net income $47.0 million, after a 2024 loss of $1,118.6 million driven by $1,153.8 million of goodwill and intangible impairments; no impairment in 2025.
- Geography: 51% North America, 23% Western Europe, 22% emerging markets (about $586 million, versus under $30 million in 2011), 4% other developed markets; about 7% of annual sales from China, where volume-based procurement (VBP) has cut dental consumable prices.
- Channel: about 42% of products sold through third-party distributors; Henry Schein alone was about 12% of 2025 sales. The commercial organization has over 3,000 employees.
- Priorities are Growth, Operations (Envista Business System, EBS) and People; investment goes to Spark clear aligners (one millionth case shipped in 2025), new implant systems, DTX Studio software and emerging markets, with DSOs called out as a fast-growing customer segment.
- Capital: $166.6 million of share buybacks in 2025 under a $250 million program; $1,211.7 million of cash at year end; outstanding indebtedness of approximately $1.5 billion as of February 6, 2026.
- Main risks: tariffs and trade policy, China pricing controls, dependence on a few distributors, FDA/EU MDR regulation, cybersecurity and AI use, debt and convertible notes.

### [Envista Holdings Corporation Quarterly Report on Form 10-Q for the quarter ended October 2, 2026 (Q3 2026)](https://www.sec.gov/Archives/edgar/data/1757073/000175707326000087/nvst-20261002.htm)

Interim report · 2026-11-04

- Q3 2026 sales $691.5 million, +3.2% (core +2.7%: price +1.8%, volume +0.9%); nine-month sales $2,127.5 million, +8.1% (core +5.6%).
- China is the drag: Q3 core sales +3.5% in developed markets but only +0.4% in emerging markets, "despite a decrease in sales in China".
- Specialty Products & Technologies: Q3 sales $443.7 million (core +2.0%), operating margin 12.2%; emerging markets core -2.0% on China.
- Equipment & Consumables: Q3 sales $247.8 million (core +4.1%), operating margin 25.1% (17.4% a year earlier), lifted by tariff refunds, higher sales and lower amortization.
- Tariffs: after the U.S. Supreme Court struck down IEEPA tariffs in February 2026, Envista had received $28.2 million of refunds by October 2, 2026 (on about $30 million paid), booked in cost of sales.
- Q3 net income was $508.3 million, mostly from a $428.1 million non-cash foreign currency translation gain on dissolving certain legal entities.
- M&A and capital: Versah (Densah burs, osseodensification) acquired February 2, 2026 for about $54.4 million; new $300 million buyback authorized May 5, 2026; $111.2 million repurchased in nine months.
- New corporate headquarters lease in Irvine, California signed September 2, 2026 (about $34.2 million of fixed payments, commencing early 2028).

### [Envista Q3 2026 earnings call transcript](https://www.tradingkey.com/news/transcripts/262289032-)

Executive talk · Paul Keel, President and Chief Executive Officer · 2026-11-04

- Q3 2026: core sales growth of 2.7%, adjusted EBITDA +9% (about $106 million, 15.3% margin, +80 bp) and adjusted EPS +25% to $0.40; Paul Keel says the dental market showed no material shift versus the first half.
- Guidance raised again: 2026 core growth 3.75% to 4.25%, adjusted EBITDA growth 12.5% to 14%, adjusted EPS $1.54 to $1.58 (prior $1.50 to $1.55).
- China, 7%-8% of sales: business fell at a low double-digit rate as distributors destocked orthodontic inventory before VBP, a net revenue headwind of about $7 million; VBP implementation expected most likely in the first half of 2027.
- Keel expects ortho VBP to cut prices about 50% and implant prices 10% to 15%; VBP is "a good guy" for growth and "a bad guy" for margin.
- Product mix: Spark up high single digits, diagnostics and implants mid-single digits, consumables low single digits; Envista is "the #1 player" in North American diagnostics and gaining share.
- New launches: NOMAD Pro 3 handheld X-ray, Orascoptic Ultra HDL loupe, AI-assisted Endo Module for DTX Studio; a Spark design center opened in Madrid.
- Capital: net debt at 0.6x adjusted EBITDA; buybacks at about one third of annual free cash flow; M&A focus on bolt-ons in implants and a possible larger Challenger-implant deal.
- 2027: keep commercializing new products and expand gross margins across the portfolio; Keel expects "continued gross and EBITDA margin expansion" despite ortho VBP.

### [Envista (NVST) Q2 2026 earnings call transcript](https://www.fool.com/earnings/call-transcripts/2026/08/12/envista-nvst-q2-2026-earnings-call-transcript/)

Executive talk · Paul Keel, President and Chief Executive Officer · 2026-08-12

- Q2 2026 (call on August 5, 2026): sales $731 million, 5% core growth; adjusted EBITDA +28% (margin 14.7%, +230 bp); adjusted EPS $0.41, +58%; first-half core growth just over 7%.
- Guidance raised: 2026 core growth 3.5% to 4.5%, adjusted EBITDA growth 11% to 14%, adjusted EPS $1.50 to $1.55; tax rate about 26%, 2 points below the initial guide.
- Equipment & Consumables grew 8.5% core (diagnostics and consumables both high single digits) and is gaining share; Specialty Products & Technologies core +3.1%, with Spark up double digits and brackets and wires down high single digits.
- China VBP: ortho VBP 1 and implant VBP 2 both underway; Keel recalls the first implant VBP cut price about 45% but more than doubled volumes, and expects implant prices down 10% to 15% this time.
- Innovation: ZenSeal Pro bioceramic sealer, DemiPro cordless curing light, Ormco Digital Bonding extended to all bracket systems; S series implant ahead of plan with about 1/4 of sales from competitive conversion.
- M&A: three small implant acquisitions in 18 months, including Versah, which Keel calls "outsourced R&D"; deals must be "strategically aligned and financially accretive".
- Margins: Spark unit cost reduction and diagnostics software and services are levers; G&A cut by $35 million last year, with the bigger opportunity now in COGS.
- Keel's thesis: a balanced portfolio (consumables and diagnostics offsetting elective implants and ortho) and diversified geographies; an Investor Day was set for September 17, 2026.

## Questions about Envista Holdings Corporation

### What does Envista do?

Envista makes dental products under more than 30 brands, including Nobel Biocare implants, Ormco and Spark orthodontics, DEXIS imaging and Kerr consumables, for dental professionals in over 130 countries.

### What is Envista's revenue?

FY2025 sales were $2,719.5 million, up 8.3%, with net income of $47.0 million. Nine-month 2026 sales were $2,127.5 million.

### How many employees does Envista have?

Approximately 12,000 at December 31, 2025, about 3,000 of them in the U.S.

### Who leads Envista?

Paul Keel is President and Chief Executive Officer; Eric Hammes is CFO.

### What is Envista's strategy?

Envista focuses on Growth, Operations and People: commercializing new implant, orthodontic and diagnostics products, expanding margins through the Envista Business System, and growing in emerging markets and with DSOs.

_Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)_
